Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom

quote:

---

Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.
As President Donald Trump continues to threaten the pharma industry with sector-specific tariffs, more and more companies are putting money into U.S. manufacturing. On Tuesday, Roche and Regeneron hopped on this train, each announcing hefty investments to beef up their production capacities in the country.

Roche is injecting $50 billion into its U.S. footprint. That money that will go toward constructing a new gene therapy plant in Pennsylvania, an R&D center in Massachusetts and a new manufacturing site in Indiana dedicated to its continuous glucose monitoring products. Roche will also erect a new 900,000-square-foot production plant for its investigational next-generation weight loss products, though the company has yet to announce where this site will go.

Tuesday’s investment will also allow Roche to upgrade its existing sites in the U.S., which currently include 13 manufacturing plants and 15 R&D facilities. All told, the company expects to add over 12,000 new positions in the U.S., including some 6,500 construction jobs.

Importantly, once these commitments come fully online, “Roche will export medicines from the US than it imports,” according to Tuesday’s release.

---